IP Library Granted Patent US 9,079,970
Granted Patent B2
US 9,079,970 · App. 13/133,883 · Granted Jul 14, 2015

Methods and compositions for specific modulation of MCL-1

Inventors: Loren D. Walensky (Newton, MA); Michelle L. Stewart (Brookline, MA)
Assignee: Dana Farber Cancer Institute, Inc.
C07K14/4747A61K31/00G01N33/5011G01N33/57484A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,079,970
App. No.
13/133,883
Granted
Jul 14, 2015
Kind
B2
Abstract

A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.

Claims (4)

1. A peptide comprising an amino acid sequence that is at least 90% identical to RKALETLRRVGDGVQRNHETAF (SEQ ID NO: 93) wherein the peptide comprises a stabilized alpha-helix with non-natural amino acids comprising a hydrocarbon staple between relative positions i and i+3, i and i+4, or i and i+7 of the peptide.

2. The peptide of claim 1 , wherein the peptide comprises a sequence selected from the group consisting of RKALETLRRVGDGVXRNHXTAF (SEQ ID NO: 27), RKXLETXRRVGDGVQRNHETAF (SEQ ID NO: 28), RKALETLRXVGDXVQRNHETAF (SEQ ID NO: 74), RKALXTLRXVGDGVQRNHETAF (SEQ ID NO: 26), RKALETLRRVGDGVQRXHETXF (SEQ ID NO: 75), KALETLRRVGDGVXRNHXTAF (SEQ ID NO: 21), KXLETXRRVGDGVQRNHETAF (SEQ ID NO: 25), KALETLRXVGDXVQRNHETAF (SEQ ID NO: 74), KALXTLRXVGDGVQRNHETAF (SEQ ID NO: 19), and KALETLRRVGDGVQRXHETXF (SEQ ID NO: 22) wherein the X's are any amino acid.

3. The peptide of claim 2 , wherein each X is non-natural amino acid comprising a hydrocarbon staple.

4. The peptide of claim 1 , wherein the peptide comprises an affinity for MCL-1 of at least 50 μM.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 8, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039607/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2011
From: WALENSKY, LOREN D.; STEWART, MICHELLE L.
To: DANA-FABER CANCER INSTITUTE, INC.
Reel/Frame 027030/0831 →
Continuity (2)
Provisional Application 61120988 · Dec 9, 2008
Related Publication 20120172285A1 · Jul 5, 2012